Provision Language
<p><em><strong>Definitionsstrong>em>p>
<p>“<strong>Cost of Goodsstrong>” means the formula for calculating the cost of goods set by Gates attached as Schedule 7 but excluding all CEPI funding for work included in the Work Packages or Additional Work Packages and other non–repayable public or philanthropic funding received by the Partner and used to <a href=”#kt“>Developa> the <a href=”#kt“>Background Technologya> and the Project Technology and to <a href=”#kt“>Manufacturea> and market the Product for use in the Field in the Affected Territoryp>
<p><strong>WHEREAS:strong>p>
<p><strong>A.strong> CEPI is a public–private not–for–profit coalition including civil and philanthropic organizations, established: (i) to finance, coordinate and support the development of new vaccine platform technologies and new vaccines to prevent and contain infectious disease epidemics; (ii) working with its partners and relevant government agencies to ensure that vaccines developed are provided on an equitable basis to all populations who need them; and (iii) to ensure adequate stockpiles and manufacturing capacity of vaccines and vaccine platforms developed for epidemic situations.p>
<p>[…]p>
<p><strong>D.strong> This Agreement sets out the terms and conditions governing the performance of the project, funding of the project and how the results of the project will be used to further CEPI’s mission.p>
<p><span style=”text–decoration: underline;”><strong>2. PROJECT OBJECTIVESstrong>span>p>
<p><strong>2.1strong> CEPI is entering into this Agreement to further CEPI’s mission by developing a vaccine platform technology that can be available for use in outbreaks of infectious diseases with epidemic potential to enable rapid vaccine development, manufacture, scale up and clinical benefit at a cost of goods in line with the methodology to determine pricing obligations set out in the CEPI Equitable Access Policy and the Cost of Goods to address global health concerns.p>
<p><strong>2.2strong> Partner is supporting CEPI to fulfill its mission, while it is interested to advance the Platform for the manufacture of mRNA based products.p>
<p><span style=”text–decoration: underline;”><strong>13. COMMERCIAL BENEFITS ARISING FROM COMMERCIAstrong><strong>L USEstrong>span>p>
<p><strong>13.1 Commercial Use.strong> In the event of any Commercial Use by Partner of Products, which are developed, Manufactured or commercialized by or on behalf of CEPI in the Field in an Affected Territory using Project Technology, the Partner shall: […]p>
<p style=”padding–left: 40px;”>13.1.2. comply with the CEPI Equitable Access Policy set out in the relevant CEPI Policy at Schedule 10 with respect to such Products, and subject to <span style=”text–decoration: underline;”><a href=”https://ghiaa.org/provision_document/cepi–curevac–framework–partnering–agreement–13–2/” target=”_blank” rel=”noopener“>Section 13.2a>span> below.p>
